Medication info
Pregabalin Capsule 75mg (Pregabalin)

Pregabalin Capsule 75mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
CMG Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a reddish-brown upper part and a white lower part containing white powder that is white or pale yellow in color.
Packaging
30 capsules/bottle
Approval status
Active

MFDS item code 201603605 · Approved 2016.06.20 · Insurance code 648603330

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
This medication is administered orally as pregabalin in two divided doses per day, regardless of food. Since this medication is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and, based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be withdrawn gradually over a period of at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Since its clearance is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: A supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Use is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Use is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
CMG Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It also aids in the adjunctive treatment of partial seizures in patients with epilepsy. It is effective for relief of pain associated with fibromyalgia. In other words, it is used for various neurological diseases such as neuropathic pain, partial seizures, and fibromyalgia.

How to take

Adult dose

This medication is administered orally as pregabalin in two divided doses per day, regardless of food. Since this medication is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and, based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be withdrawn gradually over a period of at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Since its clearance is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: A supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Use is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Use is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so mood or behavior changes should be closely monitored during treatment. Patients allergic to any components of this medication or with certain genetic metabolic disorders should not take it. Diabetic patients may need dosage adjustments for blood glucose control due to weight gain. If allergic reactions such as angioedema occur, the medication should be discontinued immediately. Elderly patients need to be cautious due to the risk of falls from dizziness or drowsiness, especially during initial doses. Visual changes like blurred vision may occur, and any unusual symptoms should be reported. Withdrawal symptoms such as insomnia, headaches, and nausea may occur when discontinuing use, so the dosage should be gradually reduced according to a doctor's instructions. There is a risk of drug abuse, so patients with a history of substance abuse should use this medication carefully. Patients with impaired kidney function may require dosage adjustments. Patients with heart disease should exercise caution, especially those with congestive heart failure, and consult a doctor. The risk of side effects such as respiratory depression is increased when taken with other central nervous system depressants or opioid analgesics, so caution is advised. Pregnant women should not take this medication due to the risk of fetal malformations in early pregnancy, and women of childbearing age should use effective contraceptive methods. During breastfeeding, this medication may pass into breast milk, so the mother should discuss whether to discontinue breastfeeding or the medication with her doctor. Caution is needed during activities such as driving or operating machinery due to the risk of accidents from dizziness or drowsiness. In cases of overdose, symptoms such as confusion, drowsiness, and depression may appear, and blood dialysis may be necessary. Keep out of reach of children and do not transfer to other containers for safety. If severe allergic reactions such as skin rashes, fever, or breathing difficulties occur during use, discontinue the medication immediately and consult a healthcare professional.

Side effects

  • suicidal ideation
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral swelling
  • upper airway swelling
  • dizziness
  • drowsiness
Show 203 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • elation
  • decreased libido
  • depersonalization
  • sexual arousal disorder
  • restlessness
  • agitation
  • mood lability
  • emotional dysphoria
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • apathy
  • ataxia
  • motor coordination abnormalities
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory decrease
  • calmness
  • drowsiness
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonus
  • diminished reflexes
  • motor abnormalities
  • psychomotor agitation
  • position-induced dizziness
  • hypersensitivity
  • burning sensation
  • action tremor
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • loss of taste
  • writing difficulties
  • blurred vision
  • double vision
  • indirect vision loss
  • visual disturbances
  • visual field loss
  • photophobia
  • dry eye
  • eye swelling
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear production
  • eye irritation
  • mydriasis
  • oscillopsia
  • changes in depth perception
  • strabismus
  • brightness of vision
  • vertigo
  • auditory hypersensitivity
  • first-degree heart block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • nasal bleeding
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tightness
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • flatulence
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory decrease
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • cervical cramps
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle stiffness
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falling
  • feeling drunk
  • altered sensation
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • elevated alanine aminotransferase
  • increased serum creatine phosphokinase
  • elevated aspartate aminotransferase
  • increased blood glucose
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • malaise
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • state of confusion
  • agitation
  • restlessness
  • seizures
  • drowsiness
  • coma
  • death
  • intestinal obstruction
  • hypomotility obstruction
  • bloody stools
  • elevated BUN
  • tinnitus
  • skin diseases

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering, and it is recommended to keep it in a cool place between 15 and 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with a reddish-brown upper part and a white lower part containing white powder that is white or pale yellow in color.

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.